JAVELIN ENROLLS FIRST PATIENT IN STUDY OF RYLOMINE

Javelin Pharmaceuticals has treated the first patient in its Phase III clinical study of Rylomine, the company's proprietary intranasal formulation of morphine. The pivotal study will enroll 256 patients with moderate-to-severe postoperative orthopedic pain.

This study follows the company's successful completion of a 187-patient Phase IIb study in patients with acute postoperative pain. These study results showed that Rylomine provided postsurgical patients with clinically and statistically significant relief of postoperative orthopedic pain, similar to intravenous morphine.